TY - JOUR T1 - Clinical and immunological factors that distinguish COVID-19 from pandemic influenza A(H1N1) JF - medRxiv DO - 10.1101/2020.08.10.20170761 SP - 2020.08.10.20170761 AU - José Alberto Choreño-Parra AU - Luis Armando Jiménez-Álvarez AU - Alfredo Cruz-Lagunas AU - Tatiana Sofía Rodríguez-Reyna AU - Gustavo Ramírez-Martínez AU - Montserrat Sandoval-Vega AU - Diana Lizzeth Hernández-García AU - Eduardo M. Choreño-Parra AU - Yalbi I. Balderas-Martínez AU - Mariana Esther Martinez-Sanchez AU - Eduardo Márquez-García AU - Edda Shiutto AU - José Moreno-Rodríguez AU - José Omar Barreto-Rodríguez AU - Hazel Vázquez-Rojas AU - Gustavo Iván Centeno-Sáenz AU - Néstor Alvarado-Peña AU - Citlaltepetl Salinas-Lara AU - Carlos Sanchez-Garibay AU - Gabriela Hernández AU - Criselda Mendoza-Milla AU - Andrea Domínguez AU - Julio Granados AU - Lula Mena-Hernández AU - Luis Ángel Pérez-Buenfil AU - Guillermo Domínguez-Cheritt AU - Carlos Cabello-Gutiérrez AU - Cesar Luna AU - Jorge Salas-Hernández AU - Patricio Santillán-Doherty AU - Justino Regalado AU - Angélica Hernández-Martínez AU - Lorena Orozco AU - Ethel Awilda García-Latorre AU - Carmen M. Hernández-Cárdenas AU - Shabaana A. Khader AU - Albert Zlotnik AU - Joaquín Zúñiga Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/14/2020.08.10.20170761.abstract N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is a global health threat with the potential to cause severe disease manifestations in the lungs. Although clinical descriptions of COVID-19 are currently available, the factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown. Here, we compared the clinical, histopathological, and immunological characteristics of patients with COVID-19 and pandemic influenza A(H1N1). We observed a higher frequency of respiratory symptoms, increased tissue injury markers, a histological pattern of alveolar pneumonia, and higher levels of IL-1RA, TNF-α, CCL3, G-CSF, APRIL, sTNF-R1, sTNF-R2, sCD30, and sCD163 in influenza patients. Conversely, dry cough, gastrointestinal symptoms, interstitial lung pathology, increased Th1 (IL-12, IFN-γ) and Th2 (IL-4, IL-5, IL-10, IL-13) cytokine levels, along with IL-1β, IL-6, CCL11, VEGF, TWEAK, TSLP, MMP-1, and MMP-3, were observed in COVID-19 cases. We demonstrated the diagnostic potential of some clinical and immune factors to differentiate COVID-19 from pandemic influenza A(H1N1). Our data suggest that SARS-CoV-2 induces a dysbalanced polyfunctional inflammatory response that is different from the immune response against influenza. These findings might be relevant for the upcoming 2020-2021 influenza season, which is projected to be historically unique due to its convergence with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJAPC was supported by the National Council of Science and Technology of Mexico to achieve (CONACyT) his PhD degree (CONACyT-CVU 737347). The current study was supported by institutional research funds of INER and by research contracts: SECTEI/050/2020, Secretaria de Ciencia, Tecnologia e Innovacion de la Ciudad de Mexico (SECTEI CDMX); FORDECyT/10SE/2020/05/14-06 and FORDECyT/10SE/2020/05/14-07 from the Fondo Institucional de Fomento Regional para el Desarrollo Cientifico y Tecnologico y de Innovacion (FORDECyT) of the CONACyT.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (INCMNSZ, approval number: 3349) and the Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas (INER, approval number: B28-16 and B09-20) in Mexico City approved the study. All participants or their legal guardians provided written informed consent in accordance with the Declaration of Helsinki for Human Research. Clinical samples were managed according to the Mexican Constitution law NOM-012-SSA3-2012, which establishes the criteria for the execution of clinical investigations in humans.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe databases used in the current study are available from the corresponding author on reasonable request ER -